02289nam 22005055 450 991030017900332120200704123045.03-319-20741-510.1007/978-3-319-20741-4(CKB)3710000000492479(EBL)4178340(SSID)ssj0001585162(PQKBManifestationID)16265197(PQKBTitleCode)TC0001585162(PQKBWorkID)14864013(PQKB)11195121(DE-He213)978-3-319-20741-4(MiAaPQ)EBC4178340(PPN)19051826X(EXLCZ)99371000000049247920151015d2015 u| 0engur|n|---|||||txtccrGuide to Targeted Therapies: Treatment Resistance in Lung Cancer /by Federico Cappuzzo1st ed. 2015.Cham :Springer International Publishing :Imprint: Adis,2015.1 online resource (71 p.)Description based upon print version of record.3-319-20740-7 Includes bibliographical references.Introduction -- Therapy options for advanced NSCLC -- Resistance to EGFR TKIs -- Overcoming EGFR-TKI resistance -- Resistance to crizotinib and therapeutic options -- Resistance to angiogenic drugs and therapeutics options.- Conclusions.This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current and emerging therapies and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of treatment resistance in lung cancer as well as a summary of current therapies will benefit from this succinct guide.Oncology  Oncologyhttps://scigraph.springernature.com/ontologies/product-market-codes/H33160Oncology  .Oncology.616.994Cappuzzo Federicoauthttp://id.loc.gov/vocabulary/relators/aut755671BOOK9910300179003321Guide to Targeted Therapies: Treatment Resistance in Lung Cancer2528722UNINA